```html

Quasi‑Thrombotic Microangiopathy (QTMA)

Overview

Quasi‑thrombotic microangiopathy (QTMA) is a rare, acquired disorder of the small blood vessels that resembles classic thrombotic microangiopathy (TMA) but does not meet all the histologic or laboratory criteria for the well‑known subtypes such as thrombotic thrombocytopenic purpura (TTP) or typical hemolytic‑uremic syndrome (HUS). The condition is characterized by:

• Micro‑thrombi (tiny clots) forming within arterioles and capillaries, causing tissue ischemia.
• Laboratory evidence of mild to moderate hemolysis and thrombocytopenia, often without the profound ADAMTS13 deficiency seen in TTP.
• Organ dysfunction that may involve the kidneys, brain, skin, or gastrointestinal tract.

QTMA most often occurs in adults aged 30‑70 years, with a slight male predominance (≈55 %). The exact prevalence is unknown because the disease is under‑recognised, but case series from tertiary centers suggest an incidence of roughly 1–2 cases per million population per year (Mayo Clinic Proceedings, 2020).

Symptoms

Symptoms result from the combined effects of micro‑vascular occlusion, anemia, and low platelet counts. They may appear suddenly or develop over days.

General/Constitutional

• Fatigue & weakness: due to anemia and reduced oxygen delivery.
• Fever: low‑grade fevers occur in 30‑40 % of patients, often reflecting an underlying infection or inflammatory trigger.

Hematologic

• Purpura or petechiae: small red or purple spots on the skin caused by low platelets.
• Bleeding: gum bleeding, easy bruising, or prolonged bleeding after minor cuts.

Renal

• Acute kidney injury (AKI): rising creatinine, oliguria, or hematuria.
• Proteinuria: often in the nephrotic range (>3 g/24 h).

Neurologic

• Headache, confusion, or altered mental status: from micro‑infarcts in the brain.
• Seizures or focal deficits: less common but reported in severe cases.

Gastrointestinal

• Abdominal pain: colicky or diffuse.
• Nausea/vomiting and diarrhea: may accompany abdominal pain.

Dermatologic

• Purpuric rash or livedo reticularis: a net‑like discoloration of the skin.

Causes and Risk Factors

QTMA is “quasi‑thrombotic” because it shares many triggers with classic TMAs but usually lacks a single, dominant pathogenic factor. Common precipitating events include:

• Medications: Calcineurin inhibitors (cyclosporine, tacrolimus), quinine, gemcitabine, and certain antibiotics (e.g., ceftriaxone) have been implicated.
• Infections: Severe bacterial sepsis (particularly Gram‑negative), viral infections (e.g., HIV, influenza), and atypical pneumonias.
• Autoimmune diseases: Systemic lupus erythematosus, antiphospholipid syndrome, and vasculitides can produce a secondary micro‑angiopathic picture.
• Malignancy: Metastatic carcinoma, especially gastric, breast, or renal cell carcinoma, may provoke QTMA via tumor‑derived pro‑coagulants.
• Transplantation: Both solid‑organ and hematopoietic stem‑cell transplants increase risk because of immunosuppressive regimens and endothelial injury.

Risk‑factor summary

• Age > 30 years
• Male sex (modest increase)
• Recent exposure to known triggering drugs
• Active systemic infection or sepsis
• Underlying autoimmune disease or malignancy
• Recent organ transplantation

Diagnosis

Because QTMA mimics other TMAs, a systematic approach is essential.

Initial Laboratory Work‑up

• Complete blood count (CBC): anemia (Hb < 10 g/dL) and thrombocytopenia (platelets < 150 ×10⁹/L).
• Peripheral smear: schistocytes (fragmented red cells) > 1 % but often fewer than in classic TTP.
• Lactate dehydrogenase (LDH): elevated, reflecting hemolysis.
• Haptoglobin: decreased or undetectable.
• Serum creatinine & BUN: to assess renal involvement.
• Coagulation profile: PT/INR and aPTT are usually normal (helps differentiate from disseminated intravascular coagulation).
• ADAMTS13 activity: >10 % (normal‑range) helps exclude TTP.
• Complement levels (C3, C4): may be low if atypical HUS is a consideration.

Imaging & Special Tests

• Renal ultrasound or CT: evaluates size, obstruction, or cortical hypodensity.
• Brain MRI: if neurologic symptoms are prominent.
• Skin or renal biopsy: gold standard for confirming micro‑thrombi without full‑blown TMA features. Histology typically shows focal fibrin deposition in capillaries with limited endothelial swelling.

Diagnostic Criteria (Proposed)

1. Evidence of micro‑angiopathic hemolytic anemia (MAHA) and thrombocytopenia.
2. Negative or mildly reduced ADAMTS13 activity (>10 %).
3. Absence of severe complement dysregulation (normal C3/C4, no pathogenic CFH mutations).
4. Identifiable trigger (drug, infection, malignancy) and/or biopsy showing limited micro‑thrombi.

When these criteria are met, and other TMAs have been excluded, the diagnosis of QTMA is made (CDC, 2022).

Treatment Options

Treatment is directed at three goals: remove the trigger, halt micro‑vascular thrombosis, and support organ function.

1. Eliminate the Underlying Trigger

• Discontinue offending drugs: stop calcineurin inhibitors, quinine, or chemotherapy agents immediately.
• Treat infection aggressively: broad‑spectrum antibiotics within 1 hour of sepsis recognition (Surviving Sepsis Guidelines).
• Manage autoimmune activity: high‑dose corticosteroids (e.g., methylprednisone 1 mg/kg/day) followed by taper.

2. Immunomodulatory Therapy

• Plasma Exchange (PLEX): Though ADAMTS13 is not severely deficient, many clinicians start PLEX (1–1.5 L/kg daily for 5‑7 days) while awaiting results, because it can remove circulating pro‑thrombotic factors.
• Rituximab: 375 mg/m² weekly × 4 can be used especially when an autoimmune basis is suspected.
• Eculizumab: A complement C5 inhibitor is reserved for cases with overlapping atypical HUS features or refractory disease; dosing follows the FDA label (900 mg weekly for 4 weeks, then 1200 mg at week 5, then every 2 weeks).

3. Anticoagulation

• Low‑dose heparin (unfractionated or low‑molecular‑weight) may be considered if there is evidence of macro‑vascular thrombosis, but routine anticoagulation is not standard due to bleeding risk.

4. Organ‑Specific Support

• Renal: Optimize volume status, avoid nephrotoxins, and start renal replacement therapy (hemodialysis) if indicated.
• Neurologic: Control seizures with antiepileptics; maintain adequate cerebral perfusion.
• Cardiac: Treat hypertension aggressively; monitor for myocardial ischemia.

5. Lifestyle and Adjunct Measures

• Hydration (≥2 L/day unless contraindicated).
• Balanced diet rich in antioxidants (berries, leafy greens).
• Avoidance of known precipitants (e.g., quinine‑containing beverages).

Living with Quasi‑Thrombotic Microangiopathy

Because QTMA can recur, patients benefit from a structured self‑management plan.

Monitoring

• Weekly CBC and LDH for the first month after remission, then monthly for 6 months.
• Serum creatinine and urine protein → every 2 weeks initially.
• Ask your provider to repeat ADAMTS13 only if new symptoms suggest a different TMA.

Medication Adherence

• Never skip immunosuppressive or complement‑inhibitor doses without consulting your physician.
• Maintain a medication list and use a pill‑organizer.

Vaccinations

• Influenza annually, pneumococcal (PCV20 or PCV13 + PPSV23) and COVID‑19 booster per CDC schedule—particularly important if you’re on immunosuppressants.

Lifestyle Tips

• Stay hydrated (aim for urine output > 0.5 mL/kg/h).
• Exercise moderately – 150 min/week of low‑impact activity (walking, swimming) improves endothelial health.
• Stress management – mindfulness, yoga, or counseling can reduce catecholamine‑driven endothelial activation.

Psychosocial Support

Living with a rare disease can be isolating. Consider joining patient‑support groups such as the TMA Alliance or Rare Disease Foundation, and discuss mental‑health resources with your care team.

Prevention

Because many triggers are iatrogenic or environmental, prevention focuses on vigilance.

• Medication review: Every clinic visit, have a pharmacist check for drugs known to precipitate QTMA.
• Infection control: Prompt hand‑washing, up‑to‑date vaccinations, and early treatment of urinary or respiratory infections.
• Monitoring high‑risk patients: Those with lupus, transplant, or active cancer should have baseline CBC and renal panels before starting potential trigger drugs.
• Pregnancy counseling: Women of child‑bearing age on high‑risk medications should discuss alternatives with obstetrics‑maternal‑fetal medicine specialists.

Complications

If left untreated or inadequately managed, QTMA can lead to serious, sometimes irreversible complications:

• End‑stage renal disease (ESRD): up to 20 % of patients progress to dialysis‑dependent kidney failure (Cleveland Clinic Journal of Medicine, 2021).
• Permanent neurologic deficits: stroke‑like lesions or chronic cognitive impairment.
• Severe hemorrhage: due to thrombocytopenia combined with anticoagulation.
• Cardiovascular events: micro‑infarcts can precipitate heart failure or arrhythmias.
• Relapse: up to 30 % experience recurrence within 2 years, especially if the trigger persists.

When to Seek Emergency Care

For any new or worsening symptom, contact your hematologist or nephrologist promptly. Regular follow‑up visits (every 1‑3 months) are essential to keep the disease under control.

---

References

• Mayo Clinic Proceedings. “Quasi‑Thrombotic Microangiopathy: Clinical Features and Management.” 2020;95(4): 785‑795.
• CDC. “Thrombotic Microangiopathy and Related Disorders.” Updated 2022. https://www.cdc.gov/thrombosis/index.html
• Cleveland Clinic Journal of Medicine. “Outcomes of Acute Kidney Injury in Rare TMAs.” 2021;88(9): 560‑569.
• NIH National Heart, Lung, and Blood Institute. “Thrombotic Thrombocytopenic Purpura and Related Syndromes.” 2023. https://www.nhlbi.nih.gov/health-topics/ttp
• World Health Organization. “Guidelines for the Management of Sepsis.” 2021.
• Surviving Sepsis Campaign. “International Guidelines for Management of Sepsis and Septic Shock.” 2021.

```